dc.contributor.author | Joshi, PM | |
dc.contributor.author | Desai, D | |
dc.contributor.author | Fuziwara, S | |
dc.contributor.author | Raveenthiran, S | |
dc.contributor.author | Nafea, M | |
dc.contributor.author | Kulkarni, SB | |
dc.date.accessioned | 2022-03-16T00:38:53Z | |
dc.date.available | 2022-03-16T00:38:53Z | |
dc.date.issued | 2021 | |
dc.identifier.issn | 2149-3235 | |
dc.identifier.doi | 10.5152/tud.2021.21065 | |
dc.identifier.uri | http://hdl.handle.net/10072/413267 | |
dc.description.abstract | Objective: To define the role of tadalafil in improving outcomes of redo urethroplasty for pelvic fracture urethral injury (PFUI). PFUI is common in developing countries, invariably as a result of road traffic trauma. Repair is complex, and redo cases are even more challenging. Material and methods: This was a longitudinal prospective nonrandomized study between 2017 and 2019. Men undergoing redo-urethroplasty were nonrandomized into two groups. Group 1 received tadalafil 5 mg the next day after surgery and continued for 3 months, and group 2 did not receive tadalafil. Inclusion criteria were patients undergoing redo-urethroplasty willing to trial low-dose tadalafil post-operatively. Exclusion criteria were <18 years, females, primary cases, and complex cases such as recto-urethral fistula. Average follow-up was 19.5 months. Results: Sixty patients were enrolled (29 in group 1 and 31 in group 2). Mean age was 31 years. These patients had 1-3 prior failed urethroplasties. Most required step 3 anastomotic urethroplasty (68.3%). Success was defined as absence of symptoms and no need for surgical intervention. Failure was defined as redo ure-throplasty or >1 endoscopic intervention. Primary success was 83.3%. Success with tadalafil was 96.6%, compared to 71.0% in the non-Tadalafil group (P = .0008). Only one patient on tadalafil failed, compared with nine in the non-tadalafil group. Secondary success rate was defined as the need for a single subsequent endoscopic intervention and was 93.3%. Conclusion: In our series, there was improved outcome with using tadalafil in patients having redo urethro-plasty for PFUI. Further trials should be done to evaluate the use in all PFUI cases. | |
dc.description.peerreviewed | Yes | |
dc.publisher | Turkish Association of Urology | |
dc.relation.ispartofpagefrom | 319 | |
dc.relation.ispartofpageto | 324 | |
dc.relation.ispartofissue | 4 | |
dc.relation.ispartofjournal | Turkish Journal of Urology | |
dc.relation.ispartofvolume | 47 | |
dc.subject.fieldofresearch | Surgery | |
dc.subject.fieldofresearch | Nephrology and urology | |
dc.subject.fieldofresearchcode | 320226 | |
dc.subject.fieldofresearchcode | 320214 | |
dc.title | Redo pelvic fracture urethral injury repair: The case for tadalafil | |
dc.type | Journal article | |
dc.type.description | C1 - Articles | |
dcterms.bibliographicCitation | Joshi, PM; Desai, D; Fuziwara, S; Raveenthiran, S; Nafea, M; Kulkarni, SB, Redo pelvic fracture urethral injury repair: The case for tadalafil, Turkish Journal of Urology, 2021, 47 (4), pp. 319-324 | |
dcterms.license | https://creativecommons.org/licenses/by/4.0/ | |
dc.date.updated | 2022-03-15T23:39:59Z | |
dc.description.version | Version of Record (VoR) | |
gro.rights.copyright | © The Author(s) 2021. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. | |
gro.hasfulltext | Full Text | |
gro.griffith.author | Desai, Devang | |